Drug Profile


Alternative Names: EMD 96785; YM 103

Latest Information Update: 29 May 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck KGaA; Yamanouchi
  • Developer Merck KGaA
  • Class Anti-ischaemics; Guanidines; Small molecules; Sulfones
  • Mechanism of Action Sodium hydrogen antiporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Myocardial infarction

Most Recent Events

  • 29 May 2001 Discontinued-II for Myocardial infarction in Europe (Injection)
  • 06 Aug 1999 YM 103 is now called eniporide
  • 24 Sep 1998 Phase-II clinical trials for Myocardial infarction in Europe (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top